[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Levofloxacin, the (-)-(S)-enantiomer isolated from the racemate ofloxacin, is launched by Aventis under the trade name of Tavanic. This new oral and parenteral antibiotic belongs to the fluoroquinolone family and exerts a bactericidal activity upon a large spectrum of microorganisms, including Gram negative and Gram positive bacilli (among which Streptococcus pneunomiae), and atypical respiratory pathogens. It also has interesting pharmacokinetic properties. Besides the classical indications of other fluoroquinolones (especially complicated urinary tract infections, including pyelonephritis, and severe skin and soft tissue infections), levofloxacin is indicated for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis and community-acquired pneumonia.
Scheen
A J
AJ
Service de Médecine interne générale et Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine.
D000208:Acute Disease; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001991:Bronchitis / Q000188:drug therapy; D017714:Community-Acquired Infections / Q000188:drug therapy; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D012852:Sinusitis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D000890:Anti-Infective Agents; D000892:Anti-Infective Agents, Urinary; D064704:Levofloxacin; D015242:Ofloxacin
Pharma-clinics. Le médicament du mois. La lévofloxacine (Tavanic).